Zydus Lifesciences Ltd.

Zydus Cadila aims to launch at least two more novel drugs out of the 20 currently under discovery research programmes to become successful by 2020. It is currently working in the areas of metabolic disorders, oncology and inflammatory disorders. The company is planning to finance its drug discovery programmes, through internal resources.

A part of the Zydus Group, Cadila Healthcare had received regulatory approval to market its diabetes drug, Lipaglyn, in India last week. It expects the drug to be a blockbuster and clock over $1 billion sales a year when sold globally.